2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2329

Do Myocardial Inflammation and Microvascular Dysfunction in RA Lead to Adverse Changes in Left Ventricular Structure and Function over Time? A Longitudinal Analysis of Participants from Rheumatoid Arthritis: Study of the Myocardium

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2404

Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2205

Dual Femur Bone Density Measurements with Novel Sonographic Approach – Radiofrequency Echographic Multi Spectrometry

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2027

Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2571

Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2168

Early Start of Outpatient Physical Therapy After Knee Replacement Is Associated with More Objectively-measured Steps and Time Spent Upright

Orthopedics, Low Back Pain, & Rehabilitation Poster – ACR/ARP

9:00AM-11:00AM: Abstract Number: 2361

Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2695

Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2528

Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2391

Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2708

Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2459

Effect of Obesity and Surgical Weight Loss on Joint Surgery Hospitalizations in Psoriatic Arthritis: Data from National Inpatient Sample

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2578

Effect of Omega-3 Fatty Acids on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2275

Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis

Reproductive Issues In Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 2532

Effect of Treatment on Antiphospholipid Antibodies in SLE

SLE – Clinical Poster III: Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].